Embolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome.

Mechanisms leading to the obstruction of the microcirculation in sinusoidal obstruction syndrome (SOS) have been unclear. Because this occurs at the onset of disease, this is a potential key target for therapeutic intervention. Rats were treated with monocrotaline with or without continuous intraportal infusion of glutathione and were studied at 0.5, 1, 2, 4, 6, and 10 days after monocrotaline treatment with the use of in vivo microscopy and transmission electron microscopy. Sinusoidal perfusion decreased from days 1 through 10 with a nadir on day 4. At 12 h, numerous swollen sinusoidal endothelial cells (SECs) were observed. Subsequently, red blood cells penetrated into the space of Disse through gaps between and through swollen SEC and dissected the sinusoidal lining away from the parenchymal cells. Sinusoidal blood flow was obstructed by an embolism of aggregates of sinusoidal lining cells, red blood cells, and adherent monocytes. All changes were prevented by glutathione infusion, notably the initial swelling of SEC. SOS is initiated by changes in SEC. Microcirculatory obstruction is due to dissection of the sinusoidal lining, followed by embolization of the sinusoid by sinusoidal lining cells, compounded by aggregates of monocytes adherent in the sinusoids. Glutathione prevents SOS by preserving an intact sinusoidal barrier.

[1]  K. Weber,et al.  Myocardial matrix metalloproteinase(s): localization and activation , 1993, Molecular and Cellular Biochemistry.

[2]  G. McDonald,et al.  Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). , 2002, Seminars in liver disease.

[3]  A. D. Jones,et al.  Protein Targets of Monocrotaline Pyrrole in Pulmonary Artery Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[4]  S. Strasberg,et al.  Glutathione, lactobionate, and histidine: cryptic inhibitors of matrix metalloproteinases contained in university of wisconsin and histidine/tryptophan/ketoglutarate liver preservation solutions , 2000, Hepatology.

[5]  S. Lehmann,et al.  N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation , 2000, Bone Marrow Transplantation.

[6]  G. Kanel,et al.  Support of sinusoidal endothelial cell glutathione prevents hepatic veno‐occlusive disease in the rat , 2000, Hepatology.

[7]  S. De Flora,et al.  N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[8]  R S McCuskey,et al.  Characterization of a reproducible rat model of hepatic veno‐occlusive disease , 1999, Hepatology.

[9]  S. Tyagi,et al.  Reduction‐oxidation (redox) state regulation of extracellular matrix metalloproteinases and tissue inhibitors in cardiac normal and transformed fibroblast cells , 1996, Journal of cellular biochemistry.

[10]  S. Bearman,et al.  The syndrome of hepatic veno-occlusive disease after marrow transplantation. , 1995, Blood.

[11]  G. McDonald,et al.  Venoocclusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms , 1994, Hepatology.

[12]  G. McDonald,et al.  Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.

[13]  D. Morin,et al.  [14C]monocrotaline kinetics and metabolism in the rat. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[14]  J. Allen,et al.  Hepatic veins of monkeys with veno-occlusive disease. Sequential ultrastructural changes. , 1969, Archives of pathology.